IFN-γ release assays in tuberculosis management in selected high-risk populations

Expert Review of Molecular Diagnostics

Volumn 9, Issue 2, 2009, Pages 165-177

  Bocchino, Marialuisa ^a   Bellofiore, Barbara ^b   Matarese, Alessandro ^b   Galati, Domenico ^b   Sanduzzi, Alessandro ^b  

^a MONALDI HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Children; HIV infection; IFN y release assay; TNF a blocker; Tuberculosis

Indexed keywords

ADALIMUMAB; ANTIRETROVIRUS AGENT; BCG VACCINE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CD4 LYMPHOCYTE COUNT; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOCOMPETENCE; INFECTION RISK; MEMORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULIN TEST; TUBERCULOSIS; BIOASSAY; BLOOD; DRUG ANTAGONISM; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METHODOLOGY; MONITORING; PRACTICE GUIDELINE; RISK FACTOR; STANDARD; T LYMPHOCYTE;

BIOLOGICAL ASSAY; GUIDELINES AS TOPIC; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MONITORING, PHYSIOLOGIC; RISK FACTORS; T-LYMPHOCYTES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66549118863     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.9.2.165     Document Type: Review

References (103)

1. Small PM, Hopewell PC, Singh SP et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N. Engl. J. Med. 330, 1703-1709 (1994).
2. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6, 107-112 (1998).
3. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb. Mortal Wkly Rep. 49(RR06), 1-54 (2000).
4. von Pirquet C. Frequency of tuberculosis in childhood. JAMA 52, 675-678 (1907).
5. Wang L, Turner MO, Elwood RK et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurement. Thorax 57, 804-809 (2002).
6. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int. J. Tuberc. Lung Dis. 3, 962-975 (1993).
7. Johnson JL, Nyole S, Okwera A et al. Uganda-Case Western Reserve University Research Collaboration. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. Am. J. Respir. Crit. Care Med. 163, 824-828 (2001).
8. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am. J. Respir. Crit. Care Med. 159, 15-21 (1999).
9. Mori T, Sakatani M, Yamagishi F et al. Specific detection of tuberculosis infection: an interferon-y-based assay using new antigens. Am. J. Respir. Crit. Care Med. 170, 59-64 (2004).
10. Lalvani A, Pathan AA, McShane H et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen specific T cells. Am. J. Respir. Crit. Care Med. 163, 824-828 (2001).
11. Rothel JS, Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux imminent? Expert Rev. Anti. Infect. Ther. 3(6), 981-993 (2005).
12. Pai M, Riley LW, Colford JM Jr. Interferon-y assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4, 761-776 (2005).
13. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention. Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection. United States. MMWR Recomm. Rep. 54, 49-55 (2005).
14. National Collaborating Centre for Chronic Conditions. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. Royal College of Physicians. London, UK (2006).
15. Canadian Tuberculosis Committee. Updated recommendations on interferon release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 34, 1-13 (2008).
16. HPA Tuberculosis Programme Board (Health Protection Agency). Health Protection Agency Position Statement: on the use of interferon y release assay (IGRA) tests for tuberculosis (TB): draft for consultation. October, 2007.
17. Drobniewski F, Cobelens F, Zellweger JP. Use of y-interferon assays in low and medium prevalence countries in Europe: a consensus statement of a Wolfheze Workshop organized by KNCV/EuroTB. Vilnius Sep 2006. Euro. Surveill. 12(7), E070726.2 (2007).
18. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T-SPOT.TB) for diagnosis of tuberculosis in clinical practice. Eur. J. Clin. Microbiol. Infect. Dis. 24, 529-536 (2005).
19. Ravn P, Munk ME, Andersen AB et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis- specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin. Diagn. Lab. Immunol. 12, 491-496 (2005).
20. Lee JY, Choi HJ, Park IN et al. Comparison of two commercial interferon-y assays for diagnosing Mycobacterium tuberculosis infection. Eur. Respir. J. 28, 24-30 (2006).
21. Lalvani A, Pathan AA, Durkan H et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen- specific T cells. Lancet 357, 2017-2021 (2001).
22. Ewer K, Deeks J, Alvarez L et al. Comparison of T cell based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361, 1168-1173 (2003).
23. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 1, CD000171 (2004).
24. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19, 2109-2116 (2005).
25. Fisk TL, Hon HM, Lennox JL, Fordham von Reyn C, Horsburgh CR Jr. Detection of latent tuberculosis among HIV- infected patients after initiation of highly active antiretroviral therapy. AIDS 17, 1102-1104 (2003).
26. Swaminathan S, Subbaraman R, Venkatesan P et al. Tuberculin skin test results in HIV-infected patients in India: implications for latent tuberculosis treatment. Int. J. Tuberc. Lung Dis. 12, 168-173 (2008).
27. Chapman AL, Munkanta M, Wilkinson KA et al. Rapid detection of active and latent tuberculosis infection in HIV- positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16, 2285-2293 (2002).
28. Karam F, Mbow F, Fletcher H et al. Sensitivity of IFN-y release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS ONE 3, e1441 (2008).
29. Dheda K, Lalvani A, Miller RF et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV- infected individuals is independent of CD4 cell count. AIDS 19, 2038-2041 (2005).
30. Lawn SD, Bangani N, Vogt M et al. Utility of interferon-y ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infect. Dis. 7, 99 (2007).
31. Hill PC, Jackson-Sillah DJ, Fox A et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 3, e1379 (2008).
32. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-y test. Respir. Res. 7, 56 (2006).
33. Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int. J. Tuberc. Lung Dis. 11, 1190-1195 (2007).
34. Luetkemeyer AF, Charlebois ED, Flores L L et al. Comparison of an interferon-g release assay with tuberculin skin testing in HIV-infected individuals. Am. J. Respir. Crit. Care Med. 175, 737-742 (2007).
35. Balcells ME, Perez CM, Chanqueo L et al. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int. J. Infect. Dis. 12, 645-652 (2008).
36. Rangaka MX, Wilkinson KA, Seldon R et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am. J. Respir. Crit. Care Med. 175, 514-520 (2007).
37. Mandalakas AM, Hesseling AC, Chegou NN et al. High level of discordant IGRA results in HIV-infected adults and children. Int. J. Tuberc. Lung Dis. 12, 417-423 (2008).
38. Rangaka MX, Diwakar L, Seldon R et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin. Infect. Dis. 44, 1639-1646 (2007).
39. Raby E, Moyo M, Devendra A et al. The effects of HIV on the sensitivity of a whole blood IFN-y release assay in Zambian adults with active tuberculosis. PLoS ONE 3, e2489 (2008).
40. American Academy of Pediatrics. Tuberculosis. In: 2006 Red Book: Report of the Committee on Infectious Diseases. 27th edition. Pickering LK, Baker CJ, Long SS, McMillan JA (Eds). Elk Grove Village, IL, USA, 593-613 (2006).
41. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect. Dis. 3, 624-632 (2003).
42. Richeldi L, Ewer K, Losi M et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am. J. Respir. Crit. Care Med. 170, 288 -295 (2004).
43. Soysal A, Millington KA, Bakir M et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366, 1443-1451 (2004).
44. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and re com mend ations for research. Ann. Intern. Med. 146, 340-354 (2007).
45. Lalvani A, Millington KA. T cell-based diagnosis of childhood tuberculosis infection. Curr. Opin. Infect. Dis. 20, 264-271 (2007).
46. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 364, 2196-2203 (2004).
47. Nicol MP, Pienaar D, Wood K et al. Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy. Clin. Infect. Dis. 40, 1301-1308 (2005).
48. Thomas MM, Hinks TS, Raghuraman S et al. Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. Int. J. Tuberc. Lung Dis. 12, 651-657 (2008).
49. Jafari C, Ernst M, Kalsdorf B et al. Rapid diagnosis of smear-negative tuberculosis by bronchoalveolar lavage enzyme-linked immunospot. Am. J. Respir. Crit. Care Med. 174, 1048-1054 (2006).
50. Losi M, Bossink A, Codecasa L et al.; European Tuberculosis Network TBNET. Use of a T-cell interferon-y release assay for the diagnosis of tuberculous pleurisy. Eur. Respir. J. 30, 1173-1179 (2007).
51. Bakir M, Millington KA, Soysal A et al. Prognostic value of a T-cell-based, interferon-ybiomarker in children with tuberculosis contact. Ann. Intern. Med. 149, 777-787 (2008).
52. Richeldi L, Ewer K, Losi M et al. T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. Pediatrics 119, E1-E5 (2007).
53. Detjen AK, Keil T, Roll S et al. Interferon-yrelease assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin. Infect. Dis. 45, 322-328 (2007).
54. Dominguez J, Ruiz-Manzano J, De Souza-Galvao M et al. Comparison of two commercially available yinterferon blood tests for immunodiagnosis of tuberculosis. Clin. Vaccine Immunol. 15, 168-171 (2008).
55. Nicol MP, Davies MA, Wood K et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Pediatrics 123, 38-43 (2009).
56. Hesseling AC, Mandalakas AM, Kirchner LH et al. Highly discordant T-cell responses in individuals with recent household tuberculosis exposure. Thorax 5 DOI: 10.1136/thx.2007.085340 (2008). (Epub ahead of print).
57. Nakaoka H, Lawson L, Squire SB et al. Risk for tuberculosis among children. Emerg. Infect. Dis. 12, 1383 -1388 (2006).
58. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-yassay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 177, 1164-1170 (2008).
59. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon yassay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 61, 616-620 (2006).
60. Tsiouris SJ, Austin J, Toro P et al. Results of a tuberculosis-specific IFN-yassay in children at high risk for tuberculosis infection. Int. J. Tuberc. Lung Dis. 10, 939-941 (2006).
61. Dogra S, Narang P, Mendiratta DK et al. Comparison of a whole blood interferon-yassay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. J. Infect. 54, 267-276 (2007).
62. Okada K, Mao TE, Mori T et al. Performance of an interferon-yrelease assay for diagnosing latent tuberculosis infection in children. Epidemiol. Infect. 136, 1179-1187 (2008).
63. Higuchi K, Harada N, Mori T, Sekiya Y. Use of QuantiFERON-TB Gold to investigate tuberculosis contacts in a high school. Respirology 12, 88-92 (2007).
64. Molicotti P, Bua A, Mela G et al. Performance of QuantiFERON-TB testing in a tuberculosis outbreak at a primary school. J. Pediatr. 152, 585 -586 (2008).
65. Ohno H, Ikegami Y, Kishida et al.; Hospital Infection Control Committee. A contact investigation of the transmission of Mycobacterium tuberculosis from a nurse working in a newborn nursery and maternity ward. J. Infect. Chemother. 14, 66-71 (2008).
66. Winje BA, Oftung F, Korsvold GE et al. School based screening for tuberculosis infection in Norway: comparison of positive tuberculin skin test with interferon-yrelease assay. BMC Infect. Dis. 8, 140 (2008).
67. Petrucci R, Amer NA, Gurgel RQ et al. Interferon y, interferon-y-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection: induced-protein 10 and INF-yresponses in children with latent tuberculosis. Pediatr. Infect. Dis. J. 27, 1073-1077 (2008).
68. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of tuberculin skin testing, QuantiFERON-TB Gold and T-SPOT.TB in children. PLoS ONE 3, e2624 (2008).
69. Detjen AK, Keil T, Roll S et al. Interferon-yrelease assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin. Infect. Dis. 45, 322-328 (2007).
70. Ferrara G, Losi M, D'Amico R et al. Use i n routi ne clinica l pr act ice of t wo commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367, 1328-3134 (2006).
71. Moiton MP, Richez C, Dumoulin C, Mehsen N, Dehais J, Schaeverbeke T. Role of anti-tumour necrosis factor-atherapeutic agents in the emergence of infections. Clin. Microbiol. Infect. 12, 1151-1153 (2006).
72. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumour necrosis factor. Nat. Clin. Pract. Rheumatol. 2, 602-610 (2006).
73. Hamdi H, Mariette X, Godot V et al.; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis. Res. Ther. 8, R114 (2006).
74. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis. 194, 486-492 (2006).
75. CDC. Tuberculosis associated with blocking agents against tumor necrosis factor-a. California 2002-2003. MMWR Morb. Mortal Wkly Rep. 53, 683-686 (2004).
76. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-atreatment. Thorax 60, 800-805 (2005).
77. Greenberg JD, Reddy SM, Schloss SG et al. Comparison of an in vitro tuberculosis interferon-yassay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J. Rheumatol. 35, 770-775 (2008).
78. Sellam J, Hamdi H, Roy C et al.; RATIO (Research Axed on Tolerance of Biotherapies) Study Group. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann. Rheum. Dis. 66, 1610 -1615 (2007).
79. Efthimiou P, Sood S. QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann. Rheum. Dis. 66, 276 (2007).
80. Pratt A, Nicholl K, Kay L. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-y agents: the Newcastle (UK) experience. Rheumatology 46, 1035-1036 (2007).
81. Cobanoglu N, Ozcelik U, Kalyoncu U et al. Interferon-y assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-a blockers. Int. J. Tuberc. Lung Dis. 11, 1177-1182 (2007).
82. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S et al. Comparison of an interferon-y assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J. Rheumatol. 35, 776-781 (2008).
83. Bocchino M, Matarese A, Bellofiore B et al. Performance of two commercial blood IFN-y release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-a treatment. Eur. J. Clin. Microbiol. Infect. Dis. 27, 907-913 (2008).
84. Balato N, Ayala F, Gaudiello F et al. Comparison of tuberculin skin test and interferon-y assays in patients with moderate to severe psoriasis who are candidates for antitumour necrosis factor-a therapy. Br. J. Dermatol. 158, 847-849 (2008).
85. Takahashi H, Shigehara K, Yamamoto M et al. Interferon y assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol. Int. 27, 1143-1148 (2007).
86. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-y assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum. 59, 800-806 (2008).
87. Matulis G, Jiini P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon y assay. Ann. Rheum. Dis. 67, 84-90 (2008).
88. Lagrange PH, Simonney N, Herrmann JL. New immunological tests in the diagnosis of tuberculosis. Rev. Mal. Respir. 24, 453-472 (2007).
89. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149, 177-184 (2008).
90. Piana F, Codecasa LR, Cavallerio et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur. Respir. J. 28, 31-34 (2006).
91. Richeldi L, Luppi M, Losi M et al. Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. Leukemia 20, 379-381 (2006).
92. Ferrara G, Losi M, Meacci M et al. Routine hospital use of a new commercial whole blood interferon-y assay for the diagnosis of tuberculosis infection. Am. J. Respir. Crit. Care Med. 172, 631-635 (2005).
93. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB gold in-tube assay. Clin. Vaccine Immunol. 15, 425-432 (2008).
94. Veerapathran A, Joshi R, Goswami K et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS ONE 3, e1850 (2008).
95. Pai M, Joshi R, Dogra S, Zwerling AA et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int. J. Tuberc. Lung Dis. 13, 84-92 (2009).
96. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med. 4, e208 (2007).
97. Leyten EM, Prins C, Bossink AW et al. Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-y assay. Eur. Respir. J. 29, 1212-1216 (2007).
98. Richeldi L, Bergamini BM, Vaienti F. Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts. Eur. Respir. J. 32, 524-525 (2008).
99. Mazurek GH, Weis SE, Moonan PK et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-y release assays in persons with suspected tuberculosis. Clin. Infect. Dis. 45, 837-845 (2007).
100. Eurico Fonseca J, Lucas H, Canhao H et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases for candidates for therapy with tumor necrosis factor a inhibitors. March 2008 update. Rev. Port. Pneumol. 14, 271-283 (2008).
101. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J. Am. Acad. Dermatol. 59, 209-217 (2008).
102. Elkayam O, Balbir-Gurman A, Lidgi M, Rahav G, Weiler-Ravel D. Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-a blockers. Harefuah 146, 235-237 (2007).
103. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect. Dis. 7, 428-438 (2007).